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The complex clinical picture of  mono-neuropathy following injury of  peripheral nerve 
is often accompanied by changes in the patients’ affective states. It has been shown 
that positive allosteric modulators of  GABAA receptors can decrease nociceptive 
transmission in animal pain models. However, recent fi ndings suggest a possibility that 
at least some of  the antinociceptive effects of  benzodiazepines, related to neuropathic 
painful stimuli, may to a signifi cant degree be a consequence of  their anxiolytic action.
In this study we evaluated the possible delayed effects of  SH–I–048A, a newly–
synthesized high–effi cacy nonselective positive modulator of  GABAA receptors, on 
anxiety–like behavior and locomotor activity in Wistar rats with a previously induced 
peripheral nerve injury.
Assessment of  behavioral parameters, using spontaneous locomotor activity and 
elevated plus maze tests, was performed 48h after completion of  single-day three-
i.p. injections treatment consisting of  zero, one, two or three doses of  SH–I–048А
(10 mg/kg).
In general, rats’ behavior observed 72 h after a moderate peripheral nerve injury 
did not indicate the persistence of  sequelae of  mono-neuropathic pain. The 
rats treated with three doses of  SH–I–048А displayed an enhanced immobility 
time in the locomotor activity test, without concomitant decrease of  the total 
distance traveled. On the other hand, in the group treated with two doses of  SH–
I–048А, a decrease in the emotional reactivity in the elevated plus maze test was 
observed. Subtle changes in the regimen of  dosing of  SH–I–048А affect locomotor 
activity and anxiety-related behavior in animals with peripheral nerve injury.
Key words: benzodiazepines elevated plus maze, nerve crush injury, spontaneous 
locomotor activity, Wistar rats
INTRODUCTION
Complex pathophysiology of  peripheral nerve injury is poorly understood and is 
usually accompanied with a signifi cant comorbid burden, which commonly consists 
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of  changes in the affective state (principally depression or anxiety), among a myriad 
of  other behavioral disturbances [1]. The data regarding the importance of  these 
additional infl uences in the genesis of  neuroplastic imprinting processes related to 
pathological nociceptive memory formation are insuffi cient; in any case, they are 
modulated by changes in the GABA neurotransmission in the spinal cord [2]. In 
this vein, it was shown that GABAA receptor positive allosteric modulators, such as 
diazepam, attenuate nociceptive transmission in animal models of  neuropathic pain 
[3, 4]. Nevertheless, a recent detailed analysis of  benzodiazepine (BZ) infl uence on the 
behavior of  rats subjected to an acute nociception–inducing stimulus, such as the hot–
plate test, demonstrated that the effects of  these drugs on the structure of  the rat’s 
response to pain are more likely attributable to anxiolysis than pain modulation [5]. 
Despite their limitations, BZs are still in widespread use for the treatment of  anxiety 
disorders and insomnia [6]. They act through those populations of  GABAA receptors 
which contain an α1, α2, α3 or α5 subunit adjacent to the γ2 subunit [7]. Development of  
ligands non–selective in affi nity and effi cacy at GABAA receptors with a low potential 
for motor defi cits in animals [8,9], has been postulated as a valuable concept in the 
treatment of  both pain and comorbid anxiety side effects. On the other hand, studies 
with mice carrying point mutations at one of  the benzodiazepine–sensitive GABAA 
receptors have attributed sedation to the selective activity of  α1–containing GABAA 
receptors [10]. L–838,417, a compound with high affi nity for all four subtypes of  
sensitive GABAA receptors, but partially effective only at the α2–, α3–, and α5 GABAA 
receptor–subtypes [11], exerted an anti–hyperalgesic action in wild type rats in models 
of  infl ammatory and neuropathic pain, without unwanted sedation, motor impairment, 
and tolerance development [12]. Furthermore, this ligand reduced the activity of  
brain areas related to the sensory and discriminative component of  pain (the medial 
thalamus and contralateral primary sensory cortex) or its emotional dimension (limbic 
system and frontal association cortex) [12].
SH–I–048A is a newly–synthesized positive modu lator of  the GABAA receptor 
characterized by high affi nity and high effi cacy at all four BZ–sensitive GABAA 
receptors [13]. Biological and electrophysiological screening has shown that SH- 
ligands in general share the majority of  the general properties of  diazepam, with 
some distinctiveness, possibly attributable to the subtle differences in action at the 
four populations of  receptors [14,15]. This and similar fi ndings indicate that among 
the nonselective agonists of  GABAA receptors, even the fi nest variation in the activity 
profi le at the different subunit composition of  the functional GABAA receptor can 
grossly affect their functional properties and could also potentially provide therapeutic 
benefi t by reducing certain symptoms without producing unwanted sedation and 
delayed motor side effects. More specifi cally, SH–I–048A in a wide range of  doses 
(0.5–10 mg/kg) exerted a diminished potential to induce anxiolysis and memory 
impairment, while repeatedly administered in three 10 mg/kg doses during 24 hour 




In the present study we tested the possible delayed effects of  SH–I–048A on anxiety–
like behavior and locomotor activity in rats with a previously induced peripheral nerve 
injury, using elevated plus-maze and spontaneous locomotor activity test, respectively.
MATERIAL AND METHODS
Drugs
The novel compound SH–I–048A ((S,E)–7–bromo–5–(2–fl uorophenyl)–3–methyl–
1Hbenzo[e][1,4]diazepin–2(3H)–one) was synthesized at the Department of  Chemistry 
and Biochemistry, University of  Wisconsin—Milwaukee. SH–I–048 was dissolved/
suspended in a solvent containing 85% distilled water, 14% propylene glycol, and 1% 
Tween–80 and was administered intraperitoneally (IP) in a volume of  1 ml/kg.
Animals
Experiments were carried out on male Wistar rats (Military Farm, Belgrade, Serbia), 
weighing 180–200 g at the beginning of  the trial. All procedures in the study conformed 
to EEC Directive 86/609 and were approved by the Ethical Committee on Animal 
Experimentation of  the Faculty of  Pharmacy in Belgrade. The rats were group–housed 
(four per cage) in transparent plastic cages with tap water and food pellets available ad 
libitum and kept under standard laboratory conditions. The temperature of  the animal 
room was 22±1 °C, relative humidity 40–70%, illumination 120 lx, and 12/12 h light/
dark period (light on at 6:00 h). All handling, daily administration of  treatment and 
testing took place during the light period of  the cycle, between 9:00 and 13:00 h.
Peripheral nerve injury model
A crush injury to the right sciatic nerve was performed in order to produce the 
peripheral nerve injury model. Beforehand the rats were anesthetized with ketamine 
solution (10% Ketamidor, Richter Pharma Ag, Wels, Austria). After the right external 
thigh and buttock area had been shaved, the skin was properly prepared with an 
antiseptic solution and alcohol, and a small incision was made. The m. vastus lateralis 
and m. biceps femoralis were bluntly separated at the mid–thigh level. The nerve was 
kept in situ. At approximately 7 mm from the point of  its emergence, the common 
sciatic nerve was mobilized and traumatized by a single 30–s crush with a serrated 
hemostat [16]. After surgery animals were separated in four groups. Treatments were 
administered three times during a 24 h period (immediately after surgery, after 12 
hours and fi nally after 23 h). The treatment groups were: solvent three times (vehicle 
group); one dose of  SH–I–048A (10 mg/kg) and solvent two times; two doses of  
SH–I–048A (10 mg/kg) and solvent once and three doses of  SH–I–048A (10 mg/kg) 
(Figure 1). A control group, consisting of  sham–operated or naïve rats, was not used 
in the present experiment; instead of  that, we opted to present in fi gures the mean 
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control values for the given parameter, obtained from at least 30 animals treated once 
with the same solvent in previous experiments performed in our laboratory [17-19].
Spontaneous locomotor activity 
Single rats were placed in a clear Plexiglas chamber (40 x 25 x 35 cm) 72 h after surgery 
and corresponding treatment. Activity under dim red light (20 lux) was recorded for 
a total of  30 min, without any habituation period, using ANY–maze software. The 
observed selected parameters were the distance traveled and the time immobile, 
measured during 30 min, as well as in 5–min intervals.
Elevated plus–maze
The elevated plus–maze (EPM) apparatus was constructed of  sheet metal, with a 
black rubber fl oor. It consisted of  two opposed open arms (50 x 10 cm) with ledges 
(0.3 cm high) and two opposed enclosed arms (50 x 10 x 40 cm), connected by the 
junction area (10 x 10 cm). The whole apparatus was elevated 50 cm above the fl oor. 
Illumination in the experimental room was provided with one red neon tube fi xed 
on the ceiling above the maze. Light intensity was 10 lx on the surface of  the closed 
arms. Immediately after SLA (spontaneous locomotor activity) test, single rats were 
placed in the centre of  the maze, facing one of  the enclosed arms and were allowed to 
freely explore the apparatus during 5 minutes. The standard spatiotemporal variables 
were recorded and analyzed using the ANY–maze Video Tracking System software 
(Stoelting Co., Wood Dale, IL, USA) in accordance with our previous studies [17-19]. 
The parameters closely related to motor activity were the total distance travelled and 
closed arm entries. The primary indices of  anxiety were the percentage of  open arm 
entries and the percentage of  the time spent on open arms. An entry into an open arm 
or closed arm was scored when 90% of  the observed animal crossed the virtual line 
separating the neighboring zones, whereas an exit occurred when more than 90% of  
animal left the respective zone. 
Figure 1. The scheme of  experimental procedure, indicating 
treatments administered immediately after surgery (0 h), 12 h 
later (+ 12 h) and after 23 h (+ 23 h). Close circle represent 
one dose of  10 mg/kg of  SH–I–048A; open circle represent 
vehiculum. SLA – spontaneous locomotor activity. EPM – 
elevated plus maze. Number of  animals per each treatment 




All numerical data presented in the fi gures are given as the mean ± SEM. Behavioral 
data sets were checked for homogeneity of  variance and normality prior to analysis 
by one–way ANOVA. In order to assess the infl uence of  treatment on locomotion 
in SLA test during six 5–min intervals we used a two–way ANOVA with repeated 
measures (Treatment as between–subject factor and Time as within–subject factor). 
Where applicable, Student–Newman–Keuls’s (SNK) test for post hoc comparisons was 
also used. In the case of  signifi cant interaction, separate one–way ANOVAs were 
conducted to assess the infl uence of  factor Treatment within individual levels of  factor 
Time. Statistical analysis was performed with ANY–maze Video Tracking System 
software (Stoelting Co., Wood Dale, IL, USA) and Sigma Plot 11 (Systat Software Inc., 




The infl uence of  SH–I–048A on total distance traveled during 30 min of  monitoring 
did not reach statistical signifi cance, as assessed by a one–way ANOVA (F(3,19)=2.04, 
p=0.143; Figure 2a). However, there was a signifi cant effect of  treatment on the total 
Figure 2. The effects of  SH–I–048 on the a) total distance traveled, b) total time immobile, 
c) distance traveled in 5 min intervals, and d) time immobile in 5 min intervals in spontaneous 
locomotor activity. * p<0.05, ** p<0.01 compared to the vehiculum (VEH); + p<0.05, ++ 
p<0.01 compared to the SH–I–048 x 1 group; ## p<0.01 compared to the SH–I–048 x 2 
group. Dash lines in fi gures 2 and 3 represent the mean values of  the given parameter in the 
control group from previous experiments performed in our laboratory
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time of  immobility (F(3,19)=5.78, p=0.006; Figure 2b). SNK post hoc showed that rats 
treated with three doses of  SH–I–048A spent more time in immobility compared 
to animals treated after injury with solvent only (vehicle group) (p=0.017), as well 
as to animals treated with two or one dose of  SH–I–048A (p=0.007 and p=0.008, 
respectively).
A two–way ANOVA with repeated measures applied on the data for the distance 
traveled during six 5–min intervals revealed a signifi cant effect only for factor Time 
(F(5,95)=84.76, p<0.001; Figure 2c). The same statistical analysis for the time of  
immobility revealed a signifi cant effect for both factors, as well as for their interaction 
(Treatment: F(3,19)=5.78, p=0.006; Time: F(5,95)=48.82, p<0.001; Interaction: 
F(15,95)= 4.15, p<0.001; Figure 2d).
Elevated plus–maze
A one–way ANOVA showed a signifi cant infl uence of  treatment on the total distance 
traveled (F(3,18)=6.86, p=0.003; Figure 3a), but not on the number of  closed arm 
entries (Figure 3b). Rats treated with two doses of  SH–I–048A had longer distances 
in regard to all three other groups, as assessed with post hoc SNK’s test, demonstrating 
a profound infl uence on these activity–related parameters.
Figure 3. The effects of  SH–I–048 on the a) total distance traveled, b) number of  closed arm 
entries, c) percentage of  open arm entries, and d) percentage of  open time in the elevated 
plus–maze. * p<0.05, ** p<0.01 compared to the vehiculum (VEH); ++ p<0.01 compared to 
the SH–I–048 x 1 group; ## p<0.01 compared to the SH–I–048 x 3 group
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Regarding the anxiety–related parameters, one–way ANOVA revealed that the effect 
of  treatment on the percentage of  the time spent on open arms was signifi cant 
(F(3,18)=7.86, p=0.001; Figure 3c). SNK’s post hoc test showed that rats treated with 
two doses of  SH–I–048A spent signifi cantly more time in open arms when compared 
to vehicle animals and those treated with three or one dose of  SH–I–048A (respective 
p values: 0.027, 0.002 and 0.003). For the percentage of  open arms entries, factor 
Treatment was also signifi cant (F(3,18)=4.67, p=0.014; Figure 3d); there was a 
signifi cant difference between rats treated with two doses compared to rats treated 
with only one dose of  SH–I–048A (p=0.009).
DISCUSSION
Acute injury of  peripheral nervous tissue results in clear–cut distressing manifestations, 
involving most prominently a state of  hyperalgesia, in animals as well as in humans 
[20]. In addition to its pathophysiological complexity and immense diffi culty to 
diagnostically evaluate it in a clinical environment, the treatment of  neuropathic 
pain also proved to be very challenging. It is becoming an increasingly arduous task 
to choose not only the suitable candidate among a number of  different treatments 
for neuropathic pain, but also the right time and dosage regime [21]. To resolve this 
intricate issue considering the plentitude of  mechanisms which mediate infl ammatory 
and nociceptive processes generated by injury [22,23], in the last couple of  years many 
studies have been designed to record and analyze the comprehensive behavioral status 
of  experimental animals subjected to mechanical nerve injury, especially focusing on the 
recovery period, which is known to be very important in the process of  consolidation 
of  the pathological phenotype. One such model of  peripheral nerve injury is that of  
the crush injury of  n. ischiadicus in rats, which demonstrated feasibility in assessing 
possible modulatory infl uences of  early interventions with distinct pharmacological 
tools. Among these possible interventions, one of  the salient roles is suggested for 
GABA–ergic modulation [24].
On the other hand, studies aimed at assessing the general behavioral status of  
animals in a recovery period and the accompanying intervention are surprisingly rare 
[5]. Examination of  animals in this phase would give a useful set of  information, 
having in mind that signs of  distress, such are changes in anxiety level or general 
locomotor activity, may affect the well–being and overall prognosis, both in animals 
[25], and in humans [26]. The results of  the present crush injury study suggest that 
acute nerve injury of  moderate intensity is connected with a generally normal range 
of  locomotor and emotional reactivity output in placebo–treated rats, as assessed 
through the SLA and EPM tests 72 h after surgery. However, the animals treated with 
a novel benzodiazepine–like compound, SH–I–048A, characterized by high affi nity 
and effi cacy at all four populations of  BZ–sensitive GABAA receptors, have displayed 
an unexpected array of  differences in behavioral activity. Namely, the rats previously 
treated twice with SH–I–048A at 10 mg/kg i.p. were apparently less anxious, i.e. less 
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emotionally reactive when faced with the choice between open and closed arms of  
the maze, without clear changes in general activity, as assessed through closed arm 
entries in the EPM and the parameters from the SLA test. Furthermore, the animals 
treated with three doses of  SH–I–048A at 10 mg/kg, displayed an unusual pattern of  
decreased locomotor activity, manifested through an increased time of  immobility, 
without an accompanying decrease of  total distance traveled. Moreover, an analysis 
of  activity in six 5–min bins revealed that the majority of  the detected immobility was 
realized in the fi nal 10 min of  tracking, which is contrary to the sedative action induced 
by acute treatment with diazepam, observed as a rule in the fi rst 15 min, even without 
the habituation period, as was the case in the present study [27]. It is noteworthy to 
mention that additional kinetic investigation of  SH–I–048A could possibly indicate 
the presence of  very low residual concentrations of  the compound in brain tissue 
72h after dosing, as demonstrated for other benzodiazepine–like compounds after 
application of  similar doses. If  that would be the case, the importance of  choosing 
a ligand with a suitable subunit activity profi le, as well as the right time and dosage 
regimen for its application, becomes even more signifi cant in light of  the fi ne tuning 
of  neural plasticity related to the post-injury period and recovery [28,29].
Our study is limited by the absence of  methodological tools aimed at the objective 
assessment of  injury recovery. Gross behavioral status of  animals, assessed 72 h 
after crush injury was devoid of  clear signs of  distress. Nevertheless, more specifi c 
behavioral analysis demonstrated that animals treated moderately with a potent and 
effective benzodiazepine–like compound were in a behavioral status which could 
be regarded as desirable (decreased anxiety, normal locomotion) in the settings of  
the patient’s recovery after an acute nerve injury. On the other hand, a more intense 
previous treatment, in animals dosed three times, was connected with an apparently 
less desirable profi le, characterized by an increased immobility.
CONCLUSION
In conclusion, the present study suggests that the behavioral output of  animals 
previously subjected to peripheral nerve injury is affected by subtle changes in the 
regimen of  dosing the positive modulator of  GABAA receptors, and it supports the 
need for refi ning any treatments aimed at supporting the injured patients, which may 
have some benefi cial delayed effects.
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ODLOŽENI BIHEJVIORALNI EFEKTI SH–I–048A, NOVOG 
NESELEKTIVNOG POZITIVNOG MODULATORA GABA
A
 
RECEPTORA, NAKON POVREDE PERIFERNOG NERVA 
PACOVA
OBRADOVIĆ Lj Aleksandar, JOKSIMOVIĆ Srđan, POE M Michael, TIMIĆ 
Tamara, COOK M James, SAVIĆ M Miroslav
Kompleksna klinička slika neuropatije nakon povrede perifernog nerva često je 
praćena i promenama afektivnog stanja pacijenata. U animalnim modelima bola po-
kazano je da pozitivni alosterni modulatori GABAA receptora mogu da smanje noci-
ceptivnu transmisiju. Međutim, skorašnji nalazi ukazuju i na mogućnost da je prividni 
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antinociceptivni efekat benzodiazepina nakon delovanja akutnog bolnog stimulusa u 
značajnoj meri posledica anksiolitičnog efekta.
U ovoj studiji ispitani su mogući odloženi efekti novosintetisanog, neselektivnog 
liganda GABAA receptora (SH–I–048A) na lokomotornu aktivnost i ponašanje u vezi 
sa anksioznošću kod pacova soja Wistar prethodno podvrgnutih povredi perifernog 
nerva.
Procena bihejvioralnih parametara sprovedena je testovima spontane lokomotorne 
aktivnosti i uzdignutog plus lavirinta 48 sati nakon što su životinje u periodu od 24 
sata primile rastvarač, jednu, dve ili tri doze SH–I–048A (10 mg/kg).
Generalno, ponašanje pacova praćeno 72 sata nakon umerene povrede perifernog 
nerva nije ukazivalo na prisustvo perzistentnih posledica neuropatskog bola. Pacovi 
prethodno tretirani sa tri doze SH–I–048A ispoljili su povećano vreme imobilnosti 
u testu lokomotorne aktivnosti, bez značajnog smanjenja ukupnog pređenog puta. S 
druge strane, u grupi koja je tretirana sa dve doze SH–I–048A zapažena je smanjena 
emocionalna reaktivnost u uzdignutom plus lavirintu.
Kod životinja sa povredom perifernog nerva, suptilne razlike u režimu doziranja 
pozitivnog modulatora GABAA, mogu značajno da utiču na ponašanje vezano za 
lomotornu aktivnost i nivo anksioznosti.
